Frank Oliver Nestle

Frank Oliver Nestle

Auto-generated profile, based on publicly available information

Frank Oliver Nestle

Sanofi Research

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
NBNadine Biesemann
Nadine Biesemann
DMDaniel Margerie
Daniel Margerie
CAChristian Asbrand
Christian Asbrand
MRMarkus Rehberg
Markus Rehberg
VSVirginia Savova
Virginia Savova
MHMatthias Herrmann
Matthias Herrmann
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases affecting primarily the joints. Despite successful therapies including antibodies against tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor, only 20 to 30% of patients experience remission. We studied whether inhibiting both TNF and IL-6 would result in improved efficacy. Using backtranslation from single-cell RNA sequencing (scRNA-seq) data from individuals with RA, we hypothesized that TNF and IL-6 act synergistically on fibroblast-like synoviocytes (FLS) and T cells. Coculture of FLS from individuals with RA and T cells supported this hypothesis, revealing effects on both disease-driving pathways and biomarkers. Combining anti-TNF and anti–IL-6 antibodies in collagen-induced arthritis (CIA) mouse models resulted in sustained long-term remission, improved histology, and effects on bone remodeling pathways. These promising data initiated the development of an anti–TNF/IL-6 bispecific nanobody compound 1, with similar potencies against TNF and IL-6. We observed additive efficacy of compound 1 in a FLS/T cell coculture affecting arthritis and T helper 17 (T H 17) pathways. This nanobody compound transcript signature inversely overlapped with described RA endotypes, indicating a potential efficacy in a broader patient population. In summary, we showed superiority of a bispecific anti–TNF/IL-6 nanobody compound or combination treatment over monospecific treatments in both in vitro and in vivo models. We anticipate improved efficacy in upcoming clinical studies.

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MKMariela Kyoreva
Mariela Kyoreva
YLYing Li
Ying Li
MHMariyah Hoosenally
Mariyah Hoosenally
JHJonathan Hardman-Smart
Jonathan Hardman-Smart
KMKirsten Morrison
Kirsten Morrison
PMPaola Di Meglio
Paola Di Meglio
The AHR is an environmental sensor and transcription factor activated by a variety of man-made and natural ligands, which has recently emerged as a critical regulator of homeostasis at barrier organs such as the skin. Activation of the AHR pathway downmodulates skin inflammatory responses in animal models and psoriasis clinical samples. In this study, we identify CYP1A1 enzymatic activity as a critical regulator of beneficial AHR signaling in the context of skin inflammation. Mice constitutively expressing Cyp1a1 displayed increased CYP1A1 enzymatic activity in the skin, which resulted in exacerbated immune cell activation and skin pathology, mirroring that observed in Ahr-deficient mice. Inhibition of CYP1A1 enzymatic activity ameliorated the skin immunopathology by restoring beneficial AHR signaling. Importantly, patients with psoriasis displayed reduced activation of the AHR pathway and increased CYP1A1 enzymatic activity compared with healthy donors, suggesting that dysregulation of the AHR/CYP1A1 axis may play a role in inflammatory skin disease. Thus, modulation of CYP1A1 activity may represent a promising alternative strategy to harness the anti-inflammatory effect exerted by activation of the AHR pathway in the skin.

5 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EDEmma Dann
Emma Dann
ETErin Teeple
Erin Teeple
RERasa Elmentaite
Rasa Elmentaite
KMKerstin B Meyer
Kerstin B Meyer
GGGiorgio Gaglia
Giorgio Gaglia
STSarah A Teichmann
Sarah A Teichmann
Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.

1 September 2006 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
CCCurdin Conrad
Curdin Conrad
FNFrank O. Nestle
Frank O. Nestle


1 March 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
IEIsioma U. Egbuniwe
Isioma U. Egbuniwe
RHRobert J. Harris
Robert J. Harris
MNMano Nakamura
Mano Nakamura
FNFrank O. Nestle
Frank O. Nestle
AAArne N. Akbar
Arne N. Akbar
KLKaty E Lacy
Katy E Lacy